Short Communication

Optimising the Management of Malignant Melanoma during COVID-19

C.M. Hurley 1,2,*, L. Wrafter 1, A. Dhannoon 1,2, H. Regan 3, P.J. Regan 1,2

1 Department of Plastic & Reconstructive Surgery, University Hospital Galway, Newcastle Road, Galway, Ireland
2 Royal College of Surgeons in Ireland, St Stephen’s Green, Dublin, Ireland
3 Medical Student

ARTICLE INFO

Article history:
Received 29 August 2021
Accepted 8 September 2021
Available online 8 November 2021

Introduction

The coronavirus disease 2019 (COVID-19) continues to present challenges for healthcare systems. This has resulted in the pragmatic restructuring of plastic surgery units worldwide 1 . This includes changes to leadership, staffing capabilities, redeployment and upskilling, adjustments to elective activity, and transformed patient pathways. In March 2020, all non-urgent elective surgery was cancelled across the UK and Ireland indefinitely 2 . It is estimated that over 28 million elective surgical procedures have been cancelled worldwide during the peak of the pandemic in both public and private practice 3, 4 . During this period, many units reported a significant fall in urgent melanoma referrals, which may lead to patients presenting with advanced disease, requiring more extensive surgery, and obtaining inferior long-term outcomes 5, 6 . The authors of this paper sought to characterise their own experience of invasive and non-invasive melanoma during the COVID-19 pandemic, with insights into our units restructuring to manage the disease continually and effectively.

* Correspondence: Mr Ciaran Hurley, Specialist Registrar, Department of Plastic and Reconstructive Surgery, University Hospital Galway, Co. Galway, Republic of Ireland.
E-mail address: ciaranhurley@rcsi.ie (C.M. Hurley).

https://doi.org/10.1016/j.jpra.2021.09.004
2352-5878/© 2021 The Authors. Published by Elsevier Ltd on behalf of British Association of Plastic, Reconstructive and Aesthetic Surgeons. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
Methods

A retrospective chart review was performed on all patients diagnosed with invasive and non-invasive cutaneous melanoma between March to December of 2019 (pre-COVID-19) compared to 2020 (COVID-19 pandemic) in a single plastic surgery unit in Ireland. These months were selected as the first regional lockdown commenced in March. There were no exclusion criteria. Patient demographics, referral sources, surgical procedures, tumour characteristics, radiological findings, oncological therapies, and follow-ups were recorded. All data were anonymised and stored in Microsoft Excel (Redmond, Washington, USA).

Statistical analysis was performed using R v 3.6.3 (R Foundation for Statistical Computing, Vienna, Austria). Counts and percentages were used to summarise the distribution of categorical variables. The mean ± standard deviation (SD) and the median/interquartile range (IQR) were used to summarise the distribution of continuous normal and non-normal variables, respectively. Chi-square test of independence was used to assess the association between categorical variables. Unpaired t-test and Mann–Whitney test were used to compare the distribution of normal and non-normal variables between groups, respectively. Hypothesis testing was performed at 5% level of significance.

Results

A total of 589 patients were included in the study. Of these, 314 patients (53%) were diagnosed with invasive melanoma, compared to 275 patients (47%) diagnosed with non-invasive disease (Table 1). The mean age was statistically, significantly older in 2019 compared to 2020. The most common invasive subtype diagnosed was superficial spreading melanoma (n=165, 29%), followed by nodular (n=67, 12%), lentigo malignant melanoma (n=29, 5%), and acral melanoma (n=18, 3%). The majority of lesions were in the head and neck (n=248), the upper limb (n=126), and the lower limb (n=116). Interestingly, the majority of patients diagnosed in 2019 were referred by the general practitioner (n=231, 83%) compared to 61% (n=179) in 2020 during the COVID-19 pandemic. Overall, more patients were diagnosed with both invasive and non-invasive melanoma in 2020 than in 2019 (p<0.05). The time from referral to biopsy was significantly higher in 2020 (64 days) compared to 2019 (28 days) (p<0.05).

In terms of tumour characteristics, including the tumour Breslow thickness (BT), ulceration, perineural, and lymphovascular invasion, microsatellites and mitotic rate were not statistically significant between the two groups. Of the sentinel lymph node biopsies performed, the rate of positivity was higher in 2019 at 56% (n=28) compared to 24% (n=22) in 2020. The deposit size and presence of extracapsular extension were not significant between the two groups. Finally, the number of patients diagnosed with metastatic disease was not statistically significant between the two groups (p=0.188).

Discussion

The diminution of elective plastic surgical activity during the COVID-19 pandemic will continue to have a profound impact on the delivery of healthcare services worldwide. As the incidence of malignant melanoma continues to increase in the UK and Ireland, it has the highest increment compared to other malignancies in the past two decades⁷. Pront diagnosis and treatment are the core principle in the prevention of morbidity and mortality of the disease. Early observers during the pandemic noted significantly more aggressive disease following regional lockdowns with respect to previously controlled time periods⁶.⁸ This decrease is contrary to our units’ experience of both invasive and non-invasive melanoma during the COVID-19 pandemic thus far. We found that more patients were diagnosed with both non-invasive and invasive melanoma during the pandemic than previously.

The referral source pattern demonstrated in our results is a record of the regional lockdown effect; many people with signs and symptoms of skin cancer did not report to their general practitioner due to uncertainties surrounding COVID-19 transmission⁵. Urgent referral care pathways between primary and tertiary care centres were also disrupted, protecting the burden on hospital resources⁹. This change is reflected in the increase in time from referral to formal diagnosis in our cohort. In response to the international experience of COVID-19 and in anticipation of a significant burden on our
Table 1
Descriptive statistics of the study sample categorized by year of diagnosis

|                                | 2019 (pre-COVID-19) | 2020 (COVID-19) | p     |
|--------------------------------|---------------------|-----------------|-------|
| **Age in years, m (range)**    | 68.5 (25 – 96)      | 63.1 (24 – 91)  | <0.001|
| **Sex**                        |                     |                 | 0.573 |
| Male                           | 137 (49.5%)         | 146 (46.8%)     |       |
| Female                         | 140 (50.5%)         | 166 (53.2%)     |       |
| **Malignancy**                 |                     |                 |       |
| Non-invasive                   | 148 (53.4%)         | 127 (40.7%)     | 0.003 |
| Invasive                       | 129 (46.6%)         | 185 (59.3%)     |       |
| **Breslow thickness**          | 3.11 (3.65)         | 2.60 (3.16)     | 0.200 |
| **SLNBx status**               |                     |                 | <0.001|
| Negative                       | 22 (44.0%)          | 68 (73.1%)      |       |
| Positive                       | 28 (56.0%)          | 22 (23.7%)      |       |
| **Metastatic status**          |                     |                 | 0.188 |
| No                             | 261 (94.2%)         | 302 (96.8%)     |       |
| Yes                            | 16 (5.78%)          | 10 (3.21%)      |       |
| **Deposit size in mm**         | 3.68 (4.06)         | 6.09 (8.66)     | 0.304 |
| **Extracapsular extension**    |                     |                 | 0.167 |
| No                             | 17 (81%)            | 10 (58.8%)      |       |
| Yes                            | 4 (19.0%)           | 7 (41.2%)       |       |
| **Completion lymphadenectomy** |                     |                 | 0.034 |
| Not performed                  | 137 (89.5%)         | 296 (94.9%)     |       |
| Performed                      | 16 (10.5%)          | 14 (4.9%)       |       |
| Awaits surgery                 | 0 (0.0%)            | 2 (0.64%)       |       |
| **Number of positive nodes**   | 4.19 (4.46)         | 2.38 (1.69)     | 0.166 |
| **Largest node identified**    | 12.4 (9.03)         | 14.6 (16.8)     | 0.732 |
| **BRAF**                       |                     |                 | 0.097 |
| Negative                       | 45 (70.3%)          | 38 (69.1%)      |       |
| Positive                       | 19 (29.7%)          | 13 (23.6%)      |       |
| **Perineural invasion**        |                     |                 | 0.695 |
| Negative                       | 107 (90.7%)         | 138 (88.5%)     |       |
| Positive                       | 11 (9.32%)          | 18 (11.5%)      |       |
| **Lymphovascular invasion**    |                     |                 | 0.284 |
| Negative                       | 107 (89.9%)         | 134 (84.8%)     |       |
| Positive                       | 12 (10.1%)          | 24 (15.2%)      |       |
| **Ulceration**                 |                     |                 | 0.227 |
| Negative                       | 92 (77.3%)          | 110 (70.1%)     |       |
| Positive                       | 27 (22.7%)          | 47 (29.9%)      |       |
| **Microsatellite**             |                     |                 | 1.000 |
| Negative                       | 79 (90.8%)          | 142 (90.4%)     |       |
| Positive                       | 8 (9.20%)           | 15 (9.55%)      |       |
| **Mitosis**                    | 1.60 (3.95)         | 2.29 (4.98)     | 0.062 |

healthcare system, the Irish government reached an early agreement with the private sector to continue elective surgery on an urgent basis in private hospitals. In particular, access to local anaesthetic procedures was reliable, and elective local skin cancer cases were triaged to non-COVID-19 provider centres.

Our study demonstrated similar tumour characteristics, including BT, ulceration, and levels of perineural and lymphovascular invasion between the two cohorts. The sentinel node positivity rate was similar across both groups, and the rate of metastatic disease observed was homogenous. Westen et al. summarise an American experience, with significant increases in tumour thickness and ulceration and advanced tumour stages. Similar findings were exhibited in Spanish and Italian populations. As reflected in UK plastic surgery departments, our unit adopted a prompt telemedicine service for patients with significant increases in tumour thickness and ulceration. This strategy allowed for minimal patient contact and fast, effective, and appropriate triage of skin cancers. This structure remains in place and represents a potentially permanent shift in practice. During the pandemic, a skin cancer nurse specialist maintained patient follow-ups and triaged a dedicated email service. Finally, our plastic surgery service continued to maintain a vir-
tual complex skin cancer multidisciplinary team meeting during the pandemic, ensuring local clinical governance was adhered to in each clinical case.

Despite early international reports of the impact of the COVID-19 pandemic on the detection, management, and outcomes of invasive malignant melanomas, our study highlights that with a prompt restructuring of services, our successful management of skin cancer can persevere. While our study is limited in its capture of a short period of the COVID-19 pandemic, it records the most devastating stage and the months following. Although plastic surgery services must continue to anticipate greater caseloads due to the unpredictable nature of the virus, it is important that we reflect on our successes during the pandemic as well as forecasting a potentially difficult future with the ongoing COVID-19 pandemic.

Disclosures

Funding: No funding was sought for the preparation of this manuscript.

Conflict of Interest: None

Ethical Approval: N/A

References

1. Leng C, Challoner T, Hausien O, Fillobos G, Baden J. From chaos to a new norm: The Birmingham experience of restructuring the largest plastics department in the UK in response to the COVID-19 pandemic. J Plast Reconstr Aesthet Surg. 2020;73:2136–2141.

2. Patel NG, Reissis D, Mair M, et al. Safety of major reconstructive surgery during the peak of the COVID-19 pandemic in the United Kingdom and Ireland - multicentre national cohort study. J Plast Reconstr Aesthet Surg. 2021;74:1161–1172.

3. Collaborative C. Elective surgery cancellations due to the COVID-19 pandemic: global predictive modelling to inform surgical recovery plans. Br J Surg. 2020;107:1440–1449.

4. Joji N, Nugent N, Vadodaria S, Sankar TK. Impact of COVID-19 on aesthetic plastic surgery practice in the United Kingdom. J Plast Reconstr Aesthet Surg. 2021.

5. Rich H, O’Neill T. Major fall in urgent skin cancer referrals during the COVID-19 outbreak. J Plast Reconstr Aesthet Surg. 2021;74:644–710.

6. Weston GK, Jeong HS, Mu EW, Polsky D, Meehan SA. Impact of COVID-19 on melanoma diagnosis. Melanoma Res. 2021;31:280–281.

7. Diffey BL. The future incidence of cutaneous melanoma within the UK. Br J Dermatol. 2004;151:868–872.

8. Italiano Intergruppo Melanoma. The effect of COVID-19 emergency in the management of melanoma in Italy. Dermatol Reports. 2021;13:8972.

9. Mercille J, Turner B, Lucey DS. Ireland’s takeover of private hospitals during the COVID-19 pandemic. Health Econ Policy Law. 2021:1–6.

10. Tejera-Vaquerizo A, Cañueto J, Toll A, et al. [Estimated effect of COVID-19 lockdown on skin tumor size and survival: an exponential growth model]. Actas Dermosifiliogr (Engl Ed). 2020;111:629–638.

11. Kosomtak K, Plonczak AM, West CA. The role of teleconsultation in the management of suspected skin malignancy in plastic surgery during COVID-19 outbreak: A single centre experience. J Plast Reconstr Aesthet Surg. 2021;74:1931–1971.

12. Khshaba H, Ng L, Osmani O, Chalmers R. COVID-19 and plastic surgery: a UK plastic surgery unit experience. Eur J Plast Surg. 2020:1–4.